CYTX : Analysis & Opinions

  1. Cytori Gets More Patents, Expands IP Folder (CYTX)

    November 17, 2016
    Cytori Therapeutics continues to bolster its IP portfolio after receiving new drug patents in the US and Europe.
  2. Cytori Scleroderma Wins Orphan Drug Status (CYTX)

    November 15, 2016
    Cytori Therapeutics secured orphan drug status for its ECCS-50 drug to treat scleroderma.
  3. Cytori 3Q Loss 26 Cents a Share vs Net 15c (CYTX)

    November 11, 2016
    Cytori posted a 3Q loss and revenue below analyst estimates.
  4. BARDA Increases Cytori Therapeutics’ Contract Option (CYTX)

    September 23, 2016
    The renewed contract option indicates on-track progress of Cytori Cell Therapy, along with increased valuations.
Trading Center